Venous thromboembolism

Venous thromboembolism

This page about venous thromboembolism automatically lists related information collected from other pages of our website.

The list also includes links to brands of medicine that may be used to treat venous thromboembolism, including their consumer medicine information (CMI) leaflets, if available.

Related information - venous thromboembolism

Audience:
       

For health professionals
01 Mar 2016 Find out which tests, treatments or procedures healthcare providers and consumers should question, as recommended by Australian medical colleges.
01 Mar 2016
Recommendations from the Haematology Society of Australia and New Zealand on thrombophilia, lymphoma, venous thromboembolism, leukaemia & thrombocytopenic purpura.
For health professionals (Health professional publication)
11 Aug 2014 Data suggesting variation in plasma concentration of dabigatran (Pradaxa) affects clinical outcomes contradicts key marketing claims. These data imply that, like warfarin, close monitoring would optimise dabigatran treatment. Does this change practice?
For health professionals (CPD activity)
27 May 2014 Consider appropriate prevention of VTE in hospital inpatients. Pulmonary embolism is responsible for approximately 10% of all deaths in hospital, even though most of these deaths are largely preventable.
For health professionals (Health professional publication)
13 Mar 2014 The vitamin K antagonist warfarin can be used for the prevention and treatment of venous thromboembolism (VTE). The newer oral anticoagulants dabigatran, rivaroxaban and apixaban are all PBS subsidised for the prevention of VTE in patients undergoing total hip replacement or total knee replacement. Rivaroxaban is also PBS subsidised for treatment of acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism and prevention of recurrent VTE. Read about the place in therapy of these medicines.
For health professionals (Tool / resource)
15 Jan 2014 Use this interactive decision tool with patients who are starting oral anticoagulants.
For health professionals (Tool / resource)
02 Aug 2013 A decision tool for use with patients who are continuing on warfarin
For health professionals (Tool / resource)
02 Aug 2013 A decision tool for use with patients who are continuing on warfarin
For health professionals (Health professional publication)
01 Aug 2013 Rivaroxaban (Xarelto) is PBS listed as an alternative to parenteral anticoagulation with heparin and dose-adjusted warfarin for treatment of DVT and prevention of VTE recurrence.
For health professionals (Tool / resource)
16 Jul 2013 A decision tool for use with patients who are starting oral anticoagulants other than wafarin